Contact
searchSearch
HMP Global
Login

BCMA Test Your Knowledge

Test Your Knowledge
Quiz: How Do Patients With MM Who Received Anti-BCMA Therapy Respond to COVID-19 Vaccinations?
12/01/2021
True or false: Patients with MM who received anti-BCMA antibody-based therapy were associated with having a lack of T-cell responses following SARS-CoV-2 vaccination.
True or false: Patients with MM who received anti-BCMA antibody-based therapy were associated with having a lack of T-cell responses following SARS-CoV-2 vaccination.
True or false: Patients with MM...
12/01/2021
Oncology
Quiz
Quiz: Which of the Following Inhibitors Target BCMA in MM?
11/10/2021
Which of the following inhibitors showed an increase in BCMA surface density and a decrease in soluble BCMA levels?
Which of the following inhibitors showed an increase in BCMA surface density and a decrease in soluble BCMA levels?
Which of the following...
11/10/2021
Oncology
Test Your Knowledge
Quiz: Is Extramedullary Disease Associated with Poor Prognoses in R/R MM?
11/02/2021
True or false: In R/R MM, extramedullary disease is linked to significantly poor prognoses.
True or false: In R/R MM, extramedullary disease is linked to significantly poor prognoses.
True or false: In R/R MM,...
11/02/2021
Oncology
Quiz
Quiz: Can Anti-BCMA CAR-T Cell Therapy Cause Humoral Immune Deficiencies in R/R MM?
10/14/2021
True or false: A profound and lasting humoral immune deficiency was found after anti-BCMA CAR-T cell therapy in patients with R/R MM.
True or false: A profound and lasting humoral immune deficiency was found after anti-BCMA CAR-T cell therapy in patients with R/R MM.
True or false: A profound and...
10/14/2021
Oncology
Test Your Knowledge
Quiz: Which Cell Type is Known for BCMA Expression?
09/20/2021
Which of the following cell type is known for BCMA expression?
Which of the following cell type is known for BCMA expression?
Which of the following cell type...
09/20/2021
Oncology
Test Your Knowledge
Quiz: Responses to BCMA-Directed CAR-T Therapy for R/R MM
09/07/2021
True or false: Results from the CARTITUDE-1 trial showed that BCMA-directed CAR-T therapy yielded early, deep, and durable responses in patients with R/R MM.
True or false: Results from the CARTITUDE-1 trial showed that BCMA-directed CAR-T therapy yielded early, deep, and durable responses in patients with R/R MM.
True or false: Results from the...
09/07/2021
Oncology
Test Your Knowledge
Quiz: Does Teclistamab Therapy Display Promise in BCMA-Positive MM?
11/19/2020
True or False: Data suggest that teclistamab is a promising therapy for patients with BCMA-positive MM.
True or False: Data suggest that teclistamab is a promising therapy for patients with BCMA-positive MM.
True or False: Data suggest that...
11/19/2020
Oncology
Test Your Knowledge
Quiz: The Basics of BCMA Expression in Multiple Myeloma
10/08/2020
True or False: BCMA is expressed in nearly all MM tumor cells and serves as a potential biomarker for identifying malignant plasma cells in this patient population.
True or False: BCMA is expressed in nearly all MM tumor cells and serves as a potential biomarker for identifying malignant plasma cells in this patient population.
True or False: BCMA is expressed...
10/08/2020
Oncology
Test Your Knowledge
Quiz: Promising Role of BCMA-Directed CAR-T Therapy for R/R MM
09/25/2020
True or False: According to data from the CARTITUDE-1 trial, the BCMA-directed CAR-T therapy JNJ‑4528 was very effective and yielded 100% overall response rate in patients with relapsed or refractory MM.
True or False: According to data from the CARTITUDE-1 trial, the BCMA-directed CAR-T therapy JNJ‑4528 was very effective and yielded 100% overall response rate in patients with relapsed or refractory MM.
True or False: According to data...
09/25/2020
Oncology
Test Your Knowledge
Quiz: Can BCMA-Targeting CAR T-Cells Improve Patient Outcomes in MM?
08/26/2020
True or False: Multiple studies have demonstrated positive results with BCMA-targeting CAR T-cells for the treatment of relapsed and refractory MM.
True or False: Multiple studies have demonstrated positive results with BCMA-targeting CAR T-cells for the treatment of relapsed and refractory MM.
True or False: Multiple studies...
08/26/2020
Oncology

Recent News

News
Sintilimab Plus Anlotinib Demonstrates Promise in Relapsed/Refractory Small Cell Lung Cancer
04/02/2026
Stephanie Holland
Results from a phase 2 trial suggest that sintilimab plus anlotinib demonstrates encouraging efficacy with manageable safety among patients with relapsed/refractory small cell lung cancer (SCLC) who have a short chemotherapy-free...
Results from a phase 2 trial suggest that sintilimab plus anlotinib demonstrates encouraging efficacy with manageable safety among patients with relapsed/refractory small cell lung cancer (SCLC) who have a short chemotherapy-free...
Results from a phase 2 trial...
04/02/2026
Oncology
News
Adebrelimab Plus Chemotherapy Maintains Long-Term Survival Benefit in ES-SCLC
04/02/2026
Stephanie Holland
Updated results from the phase 3 CAPSTONE-1 trial demonstrate that adebrelimab plus chemotherapy continues to provide durable survival benefit in patients with extensive-stage small cell lung cancer.
Updated results from the phase 3 CAPSTONE-1 trial demonstrate that adebrelimab plus chemotherapy continues to provide durable survival benefit in patients with extensive-stage small cell lung cancer.
Updated results from the phase 3...
04/02/2026
Oncology
News
Lurbinectedin Plus Atezolizumab Delays Subsequent Therapy and Maintains Survival Benefit in ES-SCLC
04/02/2026
Stephanie Holland
Exploratory results from the phase 3 IMforte trial suggest that first-line treatment with lurbinectedin plus atezolizumab delays subsequent therapy and maintains overall survival benefit in patients with extensive-stage small cell lung cancer.
Exploratory results from the phase 3 IMforte trial suggest that first-line treatment with lurbinectedin plus atezolizumab delays subsequent therapy and maintains overall survival benefit in patients with extensive-stage small cell lung cancer.
Exploratory results from the...
04/02/2026
Oncology
FDA Approval
FDA Approves Brexucabtagene Autoleucel for R/R Mantle Cell Lymphoma
04/02/2026
Stephanie Holland
Based on results from the phase 2 ZUMA-2 study, the FDA approved brexucabtagene autoleucel for adult patients with relapsed/refractory mantle cell lymphoma, including those who are BTK inhibitor–naïve.
Based on results from the phase 2 ZUMA-2 study, the FDA approved brexucabtagene autoleucel for adult patients with relapsed/refractory mantle cell lymphoma, including those who are BTK inhibitor–naïve.
Based on results from the phase...
04/02/2026
Oncology
News
Consolidation Serplulimab Following Hypo-cCRT Improves Outcomes in Limited-Stage Small Cell Lung Cancer
04/02/2026
Emily Estrada
Updated results from the phase 2 ASTRUM-LC01 trial demonstrate that following concurrent Hypo-cCRT with consolidation serplulimab improves survival with manageable safety in limited-stage small cell lung cancer.
Updated results from the phase 2 ASTRUM-LC01 trial demonstrate that following concurrent Hypo-cCRT with consolidation serplulimab improves survival with manageable safety in limited-stage small cell lung cancer.
Updated results from the phase 2...
04/02/2026
Oncology
News
Izalontamab Brengitecan Plus Serplulimab Demonstrates Strong Promise in Treatment-Naïve ES-SCLC
04/01/2026
Emily Estrada
According to results from the phase 2 BL-B01D1-204-01 study, izalontamab brengitecan plus serplulimab demonstrated encouraging efficacy with manageable safety in treatment- extensive-stage small cell lung cancer.
According to results from the phase 2 BL-B01D1-204-01 study, izalontamab brengitecan plus serplulimab demonstrated encouraging efficacy with manageable safety in treatment- extensive-stage small cell lung cancer.
According to results from the...
04/01/2026
Oncology
News
Transdermal Estradiol Noninferior to LHRH Agonists in Locally Advanced Prostate Cancer
04/01/2026
Stephanie Holland
Results from a phase 3 study demonstrated that transdermal estradiol was noninferior to luteinizing hormone-releasing hormone agonists for survival outcomes among patients with locally advanced prostate cancer.
Results from a phase 3 study demonstrated that transdermal estradiol was noninferior to luteinizing hormone-releasing hormone agonists for survival outcomes among patients with locally advanced prostate cancer.
Results from a phase 3 study...
04/01/2026
Oncology
News
Etrumadenant-Based Chemoimmunotherapy Improves Survival in Metastatic Colorectal Cancer
04/01/2026
Emily Estrada
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9...
04/01/2026
Oncology
News
Distinct Immune Microenvironment Associated With Long-Term Survival in High-Grade Glioma
03/31/2026
Emily Estrada
Results from a translational analysis suggest that long-term survival in patients with high-grade glioma is associated with a distinct immune microenvironment characterized by enhanced NK cell activity and microglial activation.
Results from a translational analysis suggest that long-term survival in patients with high-grade glioma is associated with a distinct immune microenvironment characterized by enhanced NK cell activity and microglial activation.
Results from a translational...
03/31/2026
Oncology
News
Ruxolitinib Plus Venetoclax Demonstrates Safe but Limited Clinical Activity in Relapsed/Refractory AML
03/31/2026
Emily Estrada
Results from a multicenter, phase 1 trial demonstrated that ruxolitinib plus venetoclax is well tolerated but shows modest clinical activity in heavily pretreated relapsed/refractory acute myeloid leukemia.
Results from a multicenter, phase 1 trial demonstrated that ruxolitinib plus venetoclax is well tolerated but shows modest clinical activity in heavily pretreated relapsed/refractory acute myeloid leukemia.
Results from a multicenter,...
03/31/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use